Metastatix, Inc. Commences Phase 1 Clinical Trial of MSX-122 in Cancer Patients
ATLANTA--(BUSINESS WIRE)--Metastatix, Inc., an emerging pharmaceutical company focused on the development of small molecule therapeutics, today announced the commencement of a Phase 1 study with its drug candidate, MSX-122, in patients with late-stage solid tumors. The study is being conducted at The University of Texas M.D. Anderson Cancer Center in Houston, Texas.